Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

BACKGROUND: In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gore, Martin E, Griffin, Clare L, Hancock, Barry, Patel, Poulam M, Pyle, Lynda, Aitchison, Michael, James, Nicholas, Oliver, Roderick TD, Mardiak, Jozef, Hussain, Tahera, Sylvester, Richard, Parmar, Mahesh KB, Royston, Patrick, Mulders, Peter FA
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2010
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2835851/
https://ncbi.nlm.nih.gov/pubmed/20153039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(09)61921-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados